Lundbeck hands over operations in 27 markets to partners in major shake-up

Lundbeck (LUND: CO) said Tuesday it will withdraw from 27 international markets, shifting its commercial operations to Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals. The Danish company expects the handover - set for completion by December 1, 2025 - to simplify its operations while safeguarding access to its medicines.

The move, part of Lundbeck’s “Focused Innovator” strategy, will affect about 602 employees, most of whom are expected to transition to the new partners. One-off costs of roughly 390 million Danish kroner ($61 million) are anticipated this year, though the company said there will be no impact on 2025 guidance or its midterm targets.

Chief executive Charl van Zyl said the change is designed to cut complexity and redirect resources toward high-growth regions and late-stage programs in neuro-rare and neuro-specialty diseases. The new model is also expected to be margin accretive in the medium term.